Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma

Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma

Saad AlShareef,1 Christine F McDonald,2– 4 Joy Lee2,5 1Department of Medicine, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 13317-4233, Saudi Arabia; 2Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Australia; 3Institute for Breathing and S...

Full description

Bibliographic Details
Main Authors:	AlShareef S, McDonald CF, Lee J
Format:	Article
Language:	English
Published:	Dove Medical Press 2022-02-01
Series:	Journal of Asthma and Allergy
Subjects:	asthma benralizumab exacerbations omalizumab mepolizumab monoclonal antibody
Online Access:	https://www.dovepress.com/clinical-and-lung-function-outcomes-after-anti-ige-or-anti-il5-therapy-peer-reviewed-fulltext-article-JAA

Similar Items

Effects of Therapeutic Antibodies on Gene and Protein Signatures in Asthma Patients: A Comparative Systematic Review
by: Maria J. Martin, et al.
Published: (2022-01-01)

Combining Biologics Targeting Eosinophils (IL-5/IL-5R), IgE, and IL-4/IL-13 in Allergic and Inflammatory Diseases
by: Mitchell M. Pitlick, MD, et al.
Published: (2022-11-01)

Successful simultaneous targeting of IgE and IL-5 in a severe asthmatic patient selected for lung transplantation
by: Karl-Christian Bergmann, PhD, MD, et al.
Published: (2022-08-01)

Anaphylaxis to three humanized antibodies for severe asthma: a case study
by: Koichi Jingo, et al.
Published: (2020-06-01)

Evidence-Based Approach of Biologic Therapy in Bronchial Asthma
by: Adnan Liaqat, et al.
Published: (2023-06-01)

Safety and efficacy of monoclonal antibodies targeting IL-5 in severe eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials
by: Noor Alam, et al.
Published: (2023-09-01)

Elaborate biologic approval process delays care of patients with moderate-to-severe asthma
by: Esha Sehanobish, PhD, et al.
Published: (2023-05-01)

Characterization of Severe Uncontrolled Asthma in Japan: Analysis of Baseline Data from the PROSPECT Study
by: Koya T, et al.
Published: (2023-06-01)

Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction
by: Ramphul M, et al.
Published: (2021-05-01)

Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction [Corrigendum]
by: Ramphul M, et al.
Published: (2021-07-01)

Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis
by: Maria Basagaña, et al.
Published: (2024-12-01)

Unanswered questions on the use of biologics in pediatric asthma
by: Antonio Nieto, MD, PhD, et al.
Published: (2023-11-01)

Initiation, response assessment, and switch of antibody therapies in patients with severe asthma – A survey among German specialists
by: Hendrik Suhling, MD, et al.
Published: (2023-12-01)

The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review
by: Andrea Matucci, et al.
Published: (2018-08-01)

Effects of anti‐IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real‐life multicentre study (BIONIGE)
by: Marco Contoli, et al.
Published: (2022-04-01)

Pediatric severe asthma: a case series report and perspectives on anti-IgE treatment
by: Virginia Mirra, et al.
Published: (2018-02-01)

Monoclonal antibodies targeting small airways: a new perspective for biological therapies in severe asthma
by: Carlo Lombardi, et al.
Published: (2022-10-01)

Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma
by: Drick N, et al.
Published: (2020-11-01)

The effect of anti-IL5 monoclonal antibodies on regulatory and effector T cells in severe eosinophilic asthma
by: Laura Bergantini, et al.
Published: (2023-10-01)

Impact of Anti-IL5 Therapies on Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study
by: Susana Rojo-Tolosa, et al.
Published: (2023-01-01)

Biological Therapy of Severe Asthma and Nasal Polyps
by: Agamemnon Bakakos, et al.
Published: (2022-06-01)

The rationale for treating allergic asthma with anti-IgE
by: E. Hamelmann
Published: (2007-09-01)

Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty
by: Menzella F, et al.
Published: (2017-11-01)

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
by: Giulia Scioscia, et al.
Published: (2023-06-01)

Severe asthma: anti-IgE or anti-IL-5?
by: Evgenia Papathanassiou, et al.
Published: (2016-11-01)

Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series
by: Pelletier G, et al.
Published: (2022-05-01)

Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
by: R. Buhl
Published: (2007-09-01)

Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy
by: Agamemnon Bakakos, et al.
Published: (2021-04-01)

Which patients should be treated with anti-IgE?
by: K-M. Beeh
Published: (2007-09-01)

Biological therapy in severe asthma: A gem or a jam
by: Hesham Raafat
Published: (2016-02-01)

Factors influencing poor response to type 2 targeted therapies in severe asthma: a retrospective cohort study
by: Mona Al-Ahmad, et al.
Published: (2023-12-01)

Effect of the SARS-CoV-2 pandemic on treatment processes of patients with severe asthma who were managed with monoclonal antibody
by: Emel Atayık, et al.
Published: (2022-10-01)

Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study
by: Angelantonio Maglio, et al.
Published: (2023-01-01)

Severe Asthma and Biological Therapies: Now and the Future
by: Olaia Sardon-Prado, et al.
Published: (2023-09-01)

Nasal Symptoms in Asthmatic Patients under Treatment with Anti-IL-5 Monoclonal Antibodies. A Real-Life Cohort Study
by: Juan Maza-Solano, et al.
Published: (2022-11-01)

Editorial: Difficult and severe asthma in children, volume II
by: Nicola Ullmann, et al.
Published: (2023-03-01)

Anti-IgE Treatment for Disorders Other Than Asthma
by: Jeffrey Stokes
Published: (2017-09-01)

Interleukin-5 in the Pathophysiology of Severe Asthma
by: Corrado Pelaia, et al.
Published: (2019-12-01)

Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
by: Mattia Giovannini, et al.
Published: (2019-11-01)

Adverse events of anti-IL-5 drugs in patients with eosinophilic asthma: a meta-analysis of randomized controlled trials and real-world evidence-based assessments
by: Wen Li, et al.
Published: (2024-02-01)